Precigen, Inc. (PGEN)
- Previous Close
1.4000 - Open
1.4300 - Bid 1.3600 x 300
- Ask 1.4000 x 300
- Day's Range
1.3650 - 1.4550 - 52 Week Range
0.8400 - 1.8800 - Volume
535,052 - Avg. Volume
929,465 - Market Cap (intraday)
348.34M - Beta (5Y Monthly) 1.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3900 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
precigen.comRecent News: PGEN
Performance Overview: PGEN
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGEN
Valuation Measures
Market Cap
348.34M
Enterprise Value
310.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
63.28
Price/Book (mrq)
3.59
Enterprise Value/Revenue
57.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.84%
Return on Equity (ttm)
-68.94%
Revenue (ttm)
5.44M
Net Income Avi to Common (ttm)
-96.91M
Diluted EPS (ttm)
-0.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
44.76M
Total Debt/Equity (mrq)
6.91%
Levered Free Cash Flow (ttm)
-20.89M
Research Analysis: PGEN
Company Insights: PGEN
PGEN does not have Company Insights